1,2,4-Triazole/oxime hybrids as new strategy for nitric oxide donors: Synthesis, anti-inflammatory, ulceroginicity and antiproliferative activities

• A series of novel nitric oxide donating triazole/oxime hybrids was prepared.
• Most of the tested compounds showed significant anti-inflammatory activity.
• Oximes 7i and k achieved remarkable cell growth inhibition activity.
• Compound 7k exhibited high selectivity against CNS subpanel.

A series of novel nitric oxide (NO) donating triazole/oxime hybrids was prepared and evaluated for their anti-inflammatory activity and antiproliferative activity. Most of the tested compounds showed significant anti-inflammatory activity using carrageenan-induced rat paw edema method compared to indomethacin. Calculation of the ulcer indices and histopathological investigation indicated that the prepared NO-donating oximes exhibited less ulcerogenicity compared to their ketone intermediates and indomethacin. The NO-donating oximes 7i and 7k achieved remarkable cell growth inhibition activity against most of the tested cell lines. Compound 7k was found to be with high selectivity against CNS subpanel with selectivity ratio of 11.99 at GI50 level.

Novel 1,2,4-triazole/oxime hybrids as new strategy for nitric oxide donors.Figure optionsDownload as PowerPoint slide